Collplant biotechnologies reports 2024 third quarter financial results and provides corporate update

- promising results obtained from the pre-clinical study with collplant's commercial sized rhcollagen-based regenerative breast implants, demonstrating significant implant vascularization and rapid ingrowth of native tissue -innovative breast implant technology designed to address a $3.0 billion market opportunity -cash and cash equivalents balance as of september 30, 2024 was $15.4 million -conference call to be held today at 10:00 a.m. u.s. edt – rehovot, israel , nov. 27, 2024 /prnewswire/ -- collplant biotechnologies (nasdaq: clgn), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced financial results for the third quarter ending september 30, 2024, and provided a corporate update.
CLGN Ratings Summary
CLGN Quant Ranking